Fetal Growth Retardation

4
Pipeline Programs
5
Companies
5
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
SAIZENApproved
somatropin
Unknown Company
injection1996
U
SEROSTIMApproved
somatropin
Unknown Company
injection1996
U
SEROSTIM LQApproved
somatropin
Unknown Company
subcutaneous1996

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
somatropinPhase 31 trial
Active Trials
NCT00452491Completed306Est. Apr 2010
AB
AP BiosciencesTaiwan - Taipei
3 programs
fetal heart rate variabilityN/A1 trial
fetal heart rate variabilityN/A1 trial
fetal heart rate variabilityN/A1 trial
Active Trials
NCT04289350CompletedEst. Jul 2020
NCT04323865CompletedEst. Feb 2020
NCT04288037UnknownEst. Dec 2020
Roche
RocheSTAVANGER NORWAY, Norway
1 program
soluble fms-like tyrosine kinase to placental growth factor ratioN/A1 trial
Active Trials
NCT05284474Not Yet Recruiting340Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sanofisomatropin
Rochesoluble fms-like tyrosine kinase to placental growth factor ratio
AP Biosciencesfetal heart rate variability
AP Biosciencesfetal heart rate variability
AP Biosciencesfetal heart rate variability

Clinical Trials (5)

Total enrollment: 646 patients across 5 trials

NCT00452491Sanofisomatropin

MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children

Start: May 1993Est. completion: Apr 2010306 patients
Phase 3Completed
NCT05284474Rochesoluble fms-like tyrosine kinase to placental growth factor ratio

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

Start: Jun 2024Est. completion: Dec 2026340 patients
N/ANot Yet Recruiting
NCT04288037AP Biosciencesfetal heart rate variability

Fetal Heart Rate Variability and Fetal Growth Restriction

Start: May 2019Est. completion: Dec 2020
N/AUnknown
NCT04289350AP Biosciencesfetal heart rate variability

Day to Day Variation in Fetal Heart Rate Variability

Start: Sep 2018Est. completion: Jul 2020
N/ACompleted
NCT04323865AP Biosciencesfetal heart rate variability

Fetal Heart Rate Variability

Start: Jun 2018Est. completion: Feb 2020
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space